Semaglutide Slowed Biological Aging in HIV Patients Over 8 Months, Early Study Finds
Updated
Updated · The New York Times · Jun 29
Semaglutide Slowed Biological Aging in HIV Patients Over 8 Months, Early Study Finds
1 articles · Updated · The New York Times · Jun 29
Summary
Eight months of semaglutide appeared to slow biological aging in people with HIV and lipohypertrophy, based on blood biomarkers in a preliminary study led by UC San Diego's Michael Corley.
The trial tested a long-hyped idea that GLP-1 drugs such as Ozempic and Zepbound might extend health span, an area where academic evidence has so far been limited.
People with HIV were chosen because the infection is linked to accelerated aging, making them a useful group for detecting whether the drug shows an age-related signal.
GLP-1 drugs already have established benefits for weight loss, blood sugar control and cardiovascular, liver and kidney health, which researchers say could support a broader longevity case if future studies confirm it.